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With increase of health and wellness awareness, we feel interested to do an 
equity research on a pharmaceutical/healthcare company. Since the economy is 
damaged by Covid-19 pandemic, the big pharmaceuticals firms are developing 
vaccines for this virus. Therefore, we found GSK, the second largest vaccines 
firm in the world as our target company. 
 
Our consolidated report is divided into 7 parts: Executive Summary, Overview, 
Investment and Strategic, Past Analysis, Macroeconomics Environment, 
Forecast and Valuation. In this report, it will cover the following 3 parts: 
Company and Industry overview, past analysis of GSK’s financial statement 
and valuation which includes several scenarios to approximate the actual share 
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Established in 2000, by merging Glaxo Wellcome and SmithKline Beecham, 
GlaxoSmithKline PLC is a science-led global healthcare company headquartered 
in Brentford, England. GSK explores, develops, and distributes a range of products, 
segmented by three units: Pharmaceuticals (52%), Vaccines (21%), and 
Consumer Healthcare (27%). GSK is a LSE listed company, and a constituent of 
FTSE100. On 5th Nov 2020, the company had a market capitalization of £71.5bn. 
The firm has a strong presence internationally, with more than 70% of revenue 
coming from outside of Europe in 2019. In 2020 October, GSK is the sixth1 largest 
global pharmaceutical company, the second largest vaccine company after Gilead 
Science2 , as well as the largest Consumer Healthcare company after Johnson & 
Johnson. 
GSK’s products are split across three operating divisions, all of which are profitable 
over the last nine years: 
Pharmaceutical Unit is the largest division in GSK’s total revenue, accounting for 
about 52% in 2019. This unit has a broad portfolio of innovative and established 
medicines, including HIV (accounting for 28% of GSK’s pharmaceuticals sales), 
Respiratory (18%), Immune-inflammation (4%), Oncology (1%) and Established 
Pharmaceuticals3 (50%). GSK’s pharmaceutical products enjoy a leading global 
position in Respiratory and HIV treatment. The Group has an expertise in the 
respiratory area, and a strong pipeline to offset the decline in sales of the 
Advair/Seretide 4  (important revenue origin) that totaled about £1.7bn in 2019, 
decreasing by 29% from 2018. The HIV business is run through a joint venture 
between GSK (78%), Pfizer (12%) and Shionogi (10%). Its revenue jumped 3% to 
£4.9bn in 2019. HIV has become the group’s first most important pharmaceutical 
 
1 According to Forbes as of 2019, the world's six largest pharmaceutical companies by revenue are Pfizer, Novartis, Roche, 
Sanofi, and Merck & Co and GSK. 
2 Gilead is a research-based biopharmaceutical company focused on the discovery, development, and commercialization 
of innovative medicines. 
3 Established Pharmaceuticals include pharmaceuticals whose patents were expired, for instance, Advair or 
pharmaceuticals that do not belong to Oncology, HIV, Respiratory or Immune inflammation segments, Avamys/Veramyst, 
for example. 
4 Drugs to treat asthma; GSK’s previous top-selling brand Advair/Seretide continues to face aggressive competition from 
generics. 
Source: Company Data, 2019 
Source: Company Data, 2019 
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segment, with Tivicay 5  and Triumeq 6  having reached £1.6bn and £2.5bn 
respectively. GSK is investing in oncology with the acquisition of Tesaro in 2019, 
which has developed a first-line treatment for ovarian cancer and with its recent 
alliance. 
Vaccines Unit (about 21% of the group’s revenues) develops, produces, and 
distributes over 2 million vaccines every day to people across over 160 countries. 
It covers people at all stages of life and a wide array of diseases including 
childhood vaccination against diseases such as Measles and Meningitis, 
Adolescents and adults’ vaccines against HPV7 as well as older adults’ vaccines 
against influenza and whooping cough. Vaccines unit is divided by four segments: 
Meningitis, (accounting for 14% of Vaccines total revenue in 2019), Influenza (8%), 
Shingles (25%) and Established Vaccines8 (53%). 
Consumer Healthcare Unit (about 27% of 2019 revenues) develops and markets 
products in various categories, such as wellness, oral health, nutrition, and skin 
health. The group’s wellness products portfolio is broad, encompassing areas such 
as respiratory, cold and flu, nasal decongestants, allergy, smoking cessation, and 
pain management. To be noted that GSK completed its transaction with Pfizer to 
combine their Consumer Healthcare business into a world-leading Joint Venture in 
2019. 
Geographically, GSK has a significant global presence, with majority of 
revenues driven by the US, (41% of Group revenues), with Europe (24%) and 
International revenue (35%). The UK, where the Group is incorporated, contributes 
to 3% of the total sales. 
According to Eikon platform, GSK’s current9 share outstanding is more than 
5017 million with 99.09% of free float. The rest of shares are composed by 
GlaxoSmithKline Plc ESOP (Employee Share Ownership Plan) (0.72%), Mizuho 
Trust & Banking Co. Ltd (0.09%) and Individual Investors (0.01%) such as CEO 
Emma N. Walmsley. Pharma firms usually keep a large size of the free float shares 
in the market in order to diminish volatility (smaller bid-ask spread due to the large 
 
5 Tivicay, is a brand selling drugs such as Dolutegravir to treat HIV/AIDS. 
6 Triumeq is medicine used to treat HIV-1 infection in adults and in children. 
7 Human Papillomavirus is a viral infection that's passed between people through skin-to-skin contact.  
8 Established Vaccines include vaccines whose patents were expired, for instance, Infanrix or vaccines that do not belong 
to Meningitis, Influenza or Shingles segments, for example Cervarix. Cervaris is a vaccine against certain types of cancer-
causing human papillomavirus (HPV).  
9 29/12/2020 
Source: Company Data, 2019 
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number of shares available for trade) and increase liquidity. For instance, the free 
float shares represent 99.95% of Pfizer’s total shares, 93.67% in Novartis and 100% 
in Roche.   
Industry Overview 
 The global pharmaceutical manufacturing market size amounted to $324.4bn in 
2019 and is projected to grow at a compound annual growth rate (CAGR) of 13.7% 
from 2020 to 202710. The two largest pharmaceutical markets are North America 
(40.1% of global sales) and Europe (21%); however, China is the second largest 
market among individual countries. In terms of vaccines, global vaccine sale was 
valued at $46.9bn and is expected to reach $104.9bn by 2027, exhibiting a CAGR 
of 10.7% over the seven years between 2020 and 202711.  According to a report 
published by Research Cosmos, the global Consumer Healthcare market 
expected to increase at an impressive CAGR of around 9.0% from 2019 to 2025. 
Although the report didn’t take Covid-19 impact into consideration, we believe the 
short-term disruptions would not influence long term growth. Furthermore, the key 
market drivers are increase of usage of e-commerce websites and awareness to 
wellness, self-medication and aging population. 
Positive Demographics: Longer life expectancy led to a change in world 
demographic, which became the reason of higher demand for preventive and 
therapeutic healthcare products. Population over 65 years is predicted to double 
from 2017 to 2050 and based on the average growth of the last five years, the 
world population would be approximately 8.5bn in 2030. Increasing affluence, 
changing diets and lifestyles and longer lifespans are all contributing to rise 
demand for healthcare, especially in areas such as cancer and respiratory disease. 
For instance, the demand for oncology services had risen by 48% from 2005 to 
202012, driven by the rapidly aging population and improvements in cancer survival 
rates. Employment of respiratory therapists is projected to grow 19% from 2019 to 
202913, greatly faster than the average for all occupations. Growth in the middle-
aged and elderly population will lead to an increase case of respiratory diseases 
such as chronic obstructive pulmonary disease (COPD) and pneumonia. 
Additionally, Covid-19, an essential respiratory ailment, has driven the market 
 
10 Grandview Research: Pharmaceutical Manufacturing Market Size Report, 2020-2027 
11 Fortune Business Insight: Vaccine Market Size Report, 2019-2027 
12 Future Supply and Demand for Oncologists: Challenges to Assuring Access to Oncology Services. 
13 Bureau of Labor Statistics. 
Source: Eikon Platform (28/12/2020) 
Demographic changes 







 R&D spending: According to EvaluatePharma, whilst the larger Pharmaceutical 
industry presents resistance to economic changes, slow growth has been 
witnessed in R&D expenditure since 2012, with fewer breakthrough drugs being 
approved globally. As is shown in Figure 7, the average spends per New Molecular 
Entity (NME) 14  demonstrated a trend of decrease since 2013. R&D spend is 
expected to grow at a CAGR of 3.0% to 2024, lower than the CAGR of 4.2% 
between 2010 and 2018, partially due to trend to develop smaller medicines with 
lower clinical development cost burden. Moreover, pressure from generics, rising 
costs of R&D per new drug and slower growth of pharmaceutical emerging market 
(i.e., China) attribute to the phenomenon. Furthermore, according to an article15 
published by MDPI journal, they observed that 30 large pharma companies have 
constantly absorbed external innovation by leveraging M&A rather than R&D in-
licensing. However, their results indicate the absorption of external innovation did 
not increase R&D productivity (i.e., no impact on outputs and outcomes). 
Interestingly, the cumulative R&D expenditures contributed to the advancement of 
clinical trials and the number of approved drugs while it did not contribute to the 
change in total sales. 
 
 Science and Technology: The advances in science and technology give this 
sector additional highlight. For instance, the cell therapy technology and the new 
advances in functional genomics are offering researchers a more efficient way to 
develop medicines. Additionally, artificial intelligence (AI) can help to interpret the 
scale of data from generic libraries and genomics, and machine learning can be 
used to predict new pathways to develop a medicine. In Harvard University’s 
 
14 A new molecular entity (NME) is, according to the U.S. Food and Drug Administration (FDA), a drug that contains no 
active moiety that has been approved by the FDA. 
15 Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies, 
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teaching hospital, scientists diagnose potentially deadly blood diseases at a very 
early stage with the help of AI. The system could identify and predict harmful 
bacteria in blood with 95% accuracy after “learning” 25000 images of blood 
samples. Moreover, according to the Guardian report, the drugs development 
traditionally takes several years, and AI can speed the process up. Currently, the 
success rate of the new medicines has increased 10% after the introduction of AI 
technology in pharmaceutical industry. Furthermore, according to an article from 
Aranca16, the cost of developing a drug could reach approximately $2.5bn and 
could take 10-15 years to complete phase III clinical trial. With an introduction of 
AI, researchers estimate that the cost would be reduced to 70%. 
 The demand for innovation in the healthcare sector not only drives the 
improvement in health outcomes, affordability and quality, but also brings several 
opportunities for that market. In the last 5 years, institutional investors have 
pumped more than $80bn into health tech. To catch up with this trend, in 2020, 
GSK has spent £10m to open an AI research hub in London in order to seek and 
to discovery new drugs to treat cancer. 
Competition: The pharmaceutical industry is one of the most competitive 
industries in the world as there is a large number of small and large sized players, 
most of which are well-recognized by the market with a long history. Moreover, the 
strict government regulation and technology advancement in generics and biotech 
have further increased the competition since they have no option but to obey the 
new regulations and to adopt new technologies. In this situation, more and more 
companies pursue acquisitions and collaborations to enhance their pipelines and 
portfolios. In 2019 the market witnessed a significant M&A activity in oncology, 
such as the acquisition of Celgene by Bristol Myers Squibb and Allergan by Abbvie. 
 
16 Aranca is a global research and analytical firm. 
Source:EvaluatePharma, 2019 
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This fact is mainly resulted by the most expensive R&D costs and higher profit 
margin of oncology segment. 
 As is shown in the Figures 9 and 10, oncology continues to be the main R&D focus 
area in biopharma industry. Moreover, this market share is the largest among other 
segments. In this case, collaborations and acquisitions are the best way to finance 
this sector and survive in the fierce competition. In Consumer Healthcare sector, 
fast moving consumer goods (FMGG) have experienced lower barriers to 
entry and fewer regulatory hurdles. This led to the rise of niche and e-
commerce-based companies focusing on fast-adapting consumer trends. It could 
be explained by the millennial effect and digital marketing explosion. According to 
recent McKinsey research, millennials are almost four times more likely than baby 
boomers to avoid buying products from the big companies. Sectors like over-the-
counter drugs will see greater competition for deals, especially as large assets 
grow scarce, and private-equity firms provide more and more funding, which is 
partly the reason of the consolidation of Reckitt Benckiser, Procter & Gamble and 
Nestle. Further transactions are expected to materialize in the medium term. This 
is also in line with the trend of exiting of diversified big pharma companies from 
consumer-driven markets, such as simple generics, dermatology, consumer 
health and eye-care to finance investments in innovative drugs and concentrate 
their business focus. Other companies in addition to GSK that are pursuing this 
strategy include Novartis, Bayer, Eli Lilly and Merck & Co. For example, GSK 
disinvested Horlicks business in 2018 and it is selling non-core product in 
Consumer Healthcare unit to support GSK separation program 17 . Bayer is 
divesting Consumer Healthcare unit from 2018 because its Consumer Healthcare 
business has faced falling revenue in the U.S. as consumers switch from buying 
products at brick-and-mortar drugstores to online retailers. 
Pricing: In the last years, although there is introduction of technologies in 
pharmaceutical industry to reduce the uncertainty of development of medicines and 
the increase of generic drugs in the market, the price of medicines and healthcare 
products are continuously growing. According to Mckinsey’s report, the price of 
branded drugs has risen by 57% since 2014 while the generic drugs price has 
dropped by 35%. In order to reduce the expenditure of government in the pharma 
and healthcare sectors, many countries took several measures. In US, new 
“International pricing index” was established to reduce healthcare costs for 
government and for patients. In Europe and many emerging markets, there is 
 
17 In Q1 2020, GSK initiated a two-year program to prepare for the separation of the company into two entities. This 
program will be analyzed deeper in following section “Investment strategic overview”. 
Source:EvaluatePharma, 2019 
 





“international reference pricing” which is used as a primary lever for pricing control. 
In addition, Health Technology Assessments (HTAs) was created to assess if the 
price for new medicines and medical devices is fair. 
Past Analysis 
Development Track 
GSK expanded its business all over the world mainly through acquisitions. Before 
their merge in 2000, Glaxo Wellcome was the world's third-largest pharmaceutical 
company by revenues (behind Novartis and Merck). Its products portfolio included 
drugs for the treatment of migraine, asthma (Top 1 manufacturer), coldsores and 
HIV (Top 1 manufacturer). SmithKline Beecham focused more on research and 
Consumer Healthcare products (skincare and eye products), while developing a 
small number of drugs and allergy vaccines as well. These two companies merged 
in 2000, and began the journey to strengthen Pharmaceutical, Vaccine and 
Consumer Healthcare units. 
In 2006, GSK acquired the US-based Consumer Healthcare company CNS Inc. In 
2009, GSK formed a Joint Venture with Pfizer to create ViiV Healthcare, 
specializing in HIV research. In April 2014, Novartis sold its vaccine business 
to GSK and bought GSK's cancer business. At same time, Novartis formed a 
joint venture with GSK in Consumer Healthcare sector. Afterwards, Novartis’ 
Oncology unit represented 24% of its total revenue in 2015, although it only 
accounted for 6% in 2014. In 2019, Novartis has become the third largest company 
with an expertise in oncology. In the meanwhile, GSK has become the second 
largest vaccine company in the world, representing 17% of total global vaccine 
market. From this result, the deal was considered to be a win-win transaction. In 
2018, GSK & Novartis Consumer Healthcare was buyout by GSK. After one year, 
the firm established a Consumer Health joint-venture with Pfizer, becoming the 
second largest Consumer Health company in the world. In 2019, GSK acquired 
Tesaro to rebuild its oncology pipeline and return to the battle against cancer. 
Income Statement 
Overall, GSK’s revenue witnessed a consistent increase from 2015 to 2019, rising 
from £24bn to £34bn. In 2019, GSK reported that, driven by Strong Vaccines 
(+21%), Consumer Healthcare (+17%), and flat Pharmaceuticals sales, their 
total sales increased by 9.5%. The key focus for the sales is the product called 
Advair, which caused a continued negative impact. However, this is offset by sale 
of new products such as Shingrix, which added over £1bn in total sales. For FY19, 
Source: Company Data 
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the top five products by sales were shown in figure 16. The company’s top five 
products contributed to 25.7% of Group revenues in FY19, down from 27.6% 
in FY18. The decrease was primarily driven by reduction of the percentage 
contribution by Triumeq and Advair.  
As mentioned previously, GSK’s former top-selling brand Advair/Seretide 
continues to face aggressive competition from generics. The first generic copy of 
Advair – Wixela from Mylan Healthcare was launched in the US, at a 70% discount 
compared with Advair. We also noticed that Hikma Pharmaceuticals and Novartis’ 
Sandoz also have advanced FDA’s processes. However, during 2019, Norvatis’ 
Sandoz was rejected by the FDA. GSK’s patent has been off in the USA since 2010 
(device patent expired in 2016) and Advair recorded revenues above £5 billion per 
year between 2010-2013. Although GSK has already cut its price to compete for 
the threat of generic competition since 2014, revenues have been significantly 
impacted, decreasing to 1.7bn in 2019 (29% of decrease compare with 2018). 
In the past five years, GSK’s cost of sales, R&D costs and SG&A expenses always 
represent around 30%, 13% and 31% of total revenue respectively. To analyze 
GSK’s cost efficiency, we ran an analysis with ten-year period of the percentage of 
cost in total revenue among GSK and its competitors (Annex 2). Since 2013, it has 
decreased from 32.39% to 29.78%. Although it decreased in the last 7 years, 
GSK's value has always been around the average. The continuous decrease of the 
percentage reveals the profit margin improvement and the cost efficiency in GSK. 
When looking to the whole industry, Pfizer, AbbVie and AstraZeneca are firms with 
the lowest percentage in comparison with its peers where Bayer AG has the 
highest percentage during last 10 years, except 2016 and 2017. Indeed, most of 
the pharmaceutical firms have been reducing the percentage of their cost in the 
revenue, while GSK and Johnson&Johnson have slightly increased their cost 
percentage in 2019. For instance, GSK has increased its percentage from 29.78% 
to 29.86% and Johnson&Johnson climbed to 33.58% from 33.21%. Nevertheless, 
as we mentioned previously, GSK always keeps its percentage under 30% and 
there is only 1% of the difference between GSK (29.86%) and the average 
(28.86%), which shows a good performance of GSK in cost of sales 
management during the last 10 years. 
EBITDA margin increased from 29.4% to 32.5% during the last 5 years with a 
slightly decrease from 2017 to 2019, due to genericization of the high margin 
product of Advair in the US in 2019. However, net income decreased from £8.4bn 
(FY15) to £1.0bn (FY16) and recovered in the following 4 years to £5.3bn (FY19). 
The unexceptional 2015 is mainly related to net other operating income (expense), 
in which profit on disposal (£9.7bn) was much higher than transaction related 
Source: Company Data 








charges (£2.0bn) while in other years the net other operating income is negative. 
Actually, the EBIT margin (recurring) remained stable of around 23.5% and the 
core result, in another name, the EBIT (recurring) increased in line with the 
growth of revenue.  
Comparing its peers’ EBITDA Margin, GSK maintained in the middle position, 
reflecting GSK’s medium capacity to generate operating cash. It is noted the two 
companies (Novo Nordisk and Abbvie) with the highest EBITDA margin (>40%) 
focus on high value biologicals segment. Nonetheless, companies such as Sanofi, 
whose portfolio include higher generics/OTC level, have the lowest EBITDA margin 
because the generics’ prices are more accessible, and the profit margin is 
correspondingly smaller. Other companies such as GSK and Bayer AG, who 
support higher operating expenses related to a broader organization 
(Pharmaceutical, Vaccine, Consumer Healthcare) have a medium margin. 
Balance Sheet 
Total Equity decreased from 2015 to 2017 and recovered from 2018, reaching the 
lowest value of £3.5bn in 2017 and the highest value of £18bn in 2019. The 
decrease from 2015 to 2017 primarily reflected the recognition of the net other 
operating expenses (transaction-related charges), the impact of the dividends 
paid and an increase in the pension deficit, partly offset by the profit and the 
favorable exchange translation impact from the weaker Sterling rates. To be 
noted that in 2017, the impact of the dividends paid exceeded the Total profit for 
the year, leading to a negative equity value for shareholder. The significant 
increase of GSK’s Total Equity in 2019 was primarily driven by the recognition of 
interest in Consumer Healthcare JV with Pfizer. As this acquisition was a non-cash 
transaction, it resulted an increase in net assets of £15bn, which included 
intangible assets of £12.4bn and goodwill of £3.9bn. In the meanwhile, the 
capitalization ratio18 reached the lowest point of 0.2 in 2017 and recovered to 0.4 
in 2019, consistent with the change in equity. They paid 80 pence per share of 
dividends every year. In 2019, they proceeded with large payments of £3.9bn 
(FY18: £3.9bn). We consider this dividend policy as so generous that it caused 
relatively negative FCF generation (including acquisitions), consequently, the less 
space for the new investment and development. However, the fixed dividend policy 
is normal among big pharma companies, for instance, AstraZeneca paid $2.8 per 
share, since fixed dividend payment attracts investors and it’s easier to budget for 
 
18 Capitalization ratio=Equity/ (Equity + Net Debt) 
Source: Bloomberg 
 





A majority of GSK’s asset consists of other intangible assets (Indefinite life brands: 
63%; Licences, patents, amortised brands: 33%), accounting for 39% of total 
assets. The total assets remained stable until 2019, where the total assets 
increased by 37% to £8.0bn (FY 18: £5.8bn) and goodwill doubled to £10.6bn after 
acquisition of Tesaro Inc. In order to analyse the fair value of the patents, we made 
following assumptions: the future cash flows of the existing products represent a 
portion of their future revenue; their patents Net Present Value are same with 
patents value in the report and the discount rate is 5% (WACC is around 5% in our 
model). Under these assumptions, we obligate the NPV equals to patent value 
using “Goal Seek” and obtained the percentage of revenue which represents 
excess return. These percentages, in our point of view, are in the acceptable 
interval which, we could conclude, their patents are fairly valued. 
Other investments accounts for around 3% of GSK’s total asset in the last five 
years. This accounting item includes GSK’s investment in other pharma companies 
that GSK has collaboration or competition relationship. Although this non-core item 
is not a huge amount, we deem it important for GSK’s development since it offers 
GSK considerable interest income, opportunities to acquire or merger with other 
companies in the future and offset part of the loss when GSK’s competitors do 
better through appreciation of competitors’ share price. For instance, GSK holds 
14.5% of 23andMe firm’s common stock; 12.5% of Progyny, Inc; 17% of 
Theravance Biopharma and 15% of Lyell. During the first nine month of 2020, it 
reaches a value of £2576m, increasing by 60% compared with Q3 2019. In our 
point of view, this increase is resulted by the new additions of shares 19  and 
adjustment of fair value of its equity investment during the Covid-19 period. 
As expected, Net Debt increased steadily driven by acquisition activities. In 2019, 
Net Debt increased by 17% to £26.5bn with Net Leverage20 at 2.4x (FY18: 2.2x) 
as a result of the £3.9bn acquisition of Tesaro Inc as well as £0.2bn of Tesaro net 
debt, together with the £1.3bn impact from the implementation of IFRS 16. 
However, during the first nine months of 2020, GSK has decreased its debt level, 
from £33bn to £28bn. The huge decrease is primary driven by the reduction of the 
short-term borrowings (£4914m in Q3 2020 and £8216m in Q3 2019). 
In 2019, GSK’s Net Leverage of 2.4 and Net Debt of £25.8bn are relatively high 
 
19 According to the article from Simply Wall St, the Non-Executive Chairman, Jonathan Symonds, recently bought 
UK£197k worth of stock, paying UK£13.15 for each share. 
20 Net Leverage=Net Debt/EBITDA 
Source: Analyst Graph 
Source: Eikon 
 





comparing with its peers with an average Net Leverage of 1.9 and Net Debt of 
£19.28bn. To be noted, the top 2 companies (Roche and Novartis) are the sole 
pharmaceutical firms while GSK is not a fully pharmaceutical company and only a 
half of its revenue are generated from pharmaceutical unit. We consider that GSK’s 
solid business profile is partially offset by the less favorable Net Leverage ratio 
following recent acquisitions. However, we believe that the Separation Program 
(New GSK and New Consumer Healthcare) and recent divestment of non-core 
Consumer Health products will deleverage GSK in the future. 
Valuation 
Cost of Capital and Growth 
First of all, we use 10y UK Government Bonds as proxy of risk-free rate since GSK 
set in the UK and majority of investors use pounds to realize their investment. The 
FTSE100 is well diversified market portfolio for GSK. From the stock returns 
regression (2010-2020), one can achieve the raw levered beta of GSK's stock of 
0.71. However, to find a more accurate cost of equity, this beta was adjusted 
through a reversion to mean (2/3 x beta + 1/3 x 1) in order to offset the error in the 
estimate obtained, caused by the limited number of observations (130) used in the 
regression model. GSK’s beta unlevered is 0.69, is the median among its peers. 
Novo Nordisk (0.93), Roche (0.88) and Novartis AG (0.93) have a relatively high 
unlevered beta, reflecting a correspondingly high market risk. It’s normal because 
these three companies are pure Pharma companies, which are not diversified as 
its peers. For instance, besides Pharma unit, GSK, Pfizer, Merck and Sanofi also 
have Consumer Health Unit and Vaccine Unit. The rest companies (excluding the 
first three companies) share an unlevered beta with a small range from 0.65 to 
0.70.  
GSK’s cost of capital is relatively high compared with its peers. In a world where 
the risk-free rate is about 0.26%, this firm, having a credit rating of A- (S&P), can 
negotiate their debt at a cost of 2.32%. However, GSK traded bond is more 
approximate to BBB+ yield curve (2.62%) instead of A- yield curve (2.32%). This 
is because relatively high leverage among peers made its cost of debt higher.  
With the adjusted levered beta of 0.81, Debt beta of 0.31, risk free rate of 0.26% 
and Market Risk Premium of 7.21%, also considering the actual debt to Market 
Cap ratio, we arrived to the unlevered beta of 0.69 and to the unlevered cost of 
capital of 5.26% (with CAPM).  
Starting off from the unlevered cost of capital, one can run the APV model and 
figure out the Enterprise Value for each year. To note that GSK’s Capital Structure 




varies substantially during the explicit period and there is no constant WACC. In 
this case, APV model is easier to apply than other models.   
For the explicit period, the unlevered free cash flows are growing in line with GSK’s 
revenues, costs and investments projection as we mentioned previously. From 
2030 onwards, however, we expect the UFCF to growth at a constant rate based 
on a constant Return on Invested Capital (ROIC) and Reinvestment Rate (RR). 
Both ROIC and RR are roughly stable during the last 2 years of the explicit period, 
so an average of those was considered for the continuing value. To be noted that 
UFCF of last years before the perpetuity period growth at approximate a constant 
rate (2.08%), close to the one considered in the perpetuity period (2.10%).  
Alternative Scenario and Sensitive Analysis 
To complement our valuation analysis, there are additional scenarios calculated to 
obtain a more realistic valuation price. Since we introduced the new medicines and 
their successful rate are not 100%, it is assumed two extremes scenarios: 
Pessimistic, where all products in pipeline do not succeed and Optimistic, where 
all products in pipeline succeed.  
Moreover, as GSK expected in FY19 annual report, the two-year Separation 
Program (New GSK and New Consumer Healthcare) would deliver £0.7bn of 
annual savings by 2022 and £0.8 billion by 2023 across supply chain, R&D and 
support functions. The total cost estimated is £2.4bn, of which £1.6bn in cash. 
These costs are expected to fund through the divestments of non-core products 
and equity stakes. To be noted that the large increase in “Divestments” during 2020 
is mainly to cover the cash cost of this program. In our point of view, we considered 
this separation indeed will generate cost of savings since there are successful 
example previously. In 2016, GSK realized a program to reshape the 
Pharmaceuticals Units and generated a cost savings of £3bn as they expected. In 
order to analyze the effectiveness of this program, we implemented three 
scenarios regarding the amount of cost savings: Successful (£1bn in 2022, £1.1bn 
in 2023); Expectable (£0.7bn in 2022, £0.8bn in 2023) and Less Successful 
(£0.3bn in 2022 and £0.4bn in 2023). Combined these scenarios, several 
probabilities are assumed: 85% for normal scenario; 10% for the optimistic and 5% 
for the pessimistic; 10% for the successful scenario, 50% for the expectable and 
40% for the less successful. In the end, it resulted in a share price of £17.38 and 
expected return of 21.95%. Hence, we recommend a BUY position. (Appendix 3) 
Multiple and Ratio Analysis 
To compare GSK with its peers, there are three multiples selected: P/E ratio, 
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EV/EBIT and EV/EBITDA. The combination of the first two multiples could indicate 
if the stock is undervalued or overvalued. Looking to the P/E ratio, GSK (18.94) is 
highly below the average (29.65). On the other side, the EV/EBIT (17.54) is also 
under the average value (19.05). The EV/EBIT is considered to be a better 
indicator than EV/EBITDA since this industry is a capital-intensive where 
depreciation/amortization is a true economic cost. The relatively lower EV/EBIT 
and P/E ratios with a higher EBIT margin among its peers show that GSK was 
undervalued.  
ROE could be calculated as multiplication of ROA and Leverage ratio. The small 
value of ROA combining with a high value of ROE indicated that there is high level 
of debt, however, GSK is still rated as A according to the S&P, A- according to the 
Fintech, and A2 according to the Moody. These ratings show a positive expectation 
from banks and financial institutions. GSK is considered to have good debt 
repayment capacity and favorable future development. Comparing its peers, 
GSK’s ROE is on the average. 
 
 
 
 
Source: Bloomberg 
 
